ABBV-514 monotherapy and in combo with Budigalimab/Bevacizumab in NSCLC, HNSCC, & solid tumors - Clinical Trial
¿Cuál es el Propósito de este estudio?
What happens in this study?
- You'll get the study medicine through an IV every 3 weeks
- Depending on your group, you might also get:
- Budigalimab (a new medicine being tested)
- Or a standard cancer medicine
- You'll give blood and urine samples
- You'll have regular CT or MRI scans to check your health
18 years or older with Non-Small Cell Lung Cancer-(NSCLC), Head and Neck Squamous Cell Carcinoma-(HNSCC), Solid Tumors, Gastric/Esophageal, Pancreatic, High-Grade Serous Ovarian Cancer, and Triple Negative Breast Cancer
¿Quién puede participar en el Estudio?
Who can join this study?
- Adults who are 18 or older
- Have an advanced or spreading form of cancer called a solid tumor
¿Qué Implica?
Why is this study happening?
Doctors want to see if a new medicine called azirkitug (ABBV-514) is safe and works well for people with certain cancers that have spread. They're testing it by itself, or with other medicines like budigalimab or bevacizumab.
Detalles del Estudio
